IMPORTANCE Carfilzomib-lenalidomide-dexamethasone therapy yields deep responses in patients with newly diagnosed multiple myeloma (NDMM). It is important to gain an understanding of this combination's tolerability and impact on minimal residual disease (MRD) negativity because this end point has been associated with improved survival.
Recent studies indicate that 3-drug combination regimens using proteasome inhibitors and immunomodulatory drugs yield deep responses in patients with newly diagnosed multiple myeloma (NDMM). 8, 9 The combination of the selective proteasome inhibitor carfilzomib with lenalidomide and dexamethasone (CRd) was recently given to 392 patients with relapsed MM participating in a phase 3 study, resulting in an unprecedented deep response rate (31.8% complete response [CR] or better) and a median progression-free survival (PFS) of 26.3 months. 10 Furthermore, based on a phase 1/2 study that included 52 patients with NDMM, 61% achieved a stringent complete response (sCR) after at least 8 cycles. 8 Treatment with
CRd was found to have a favorable peripheral neuropathy (PN) profile (all grade: 23%; grade ≥2: 6%), which may allow for greater treatment adherence and an increased likelihood to reach negativity for minimal residual disease (MRD) compared with use of other proteasome inhibitors.
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Given that many patients with NDMM who are treated with CRd achieved the deepest level of responses recognized by current standardized criteria, there is a need to assess MRD in patients treated with CRd. Minimal residual disease negativity is associated with improved PFS and overall survival both in patients who receive stem cell transplants and in those who do not.
11- 13 Several approaches have been used to determine MRD status in MM, including multiparametric flow cytometry (MFC), 11,12,14 next-generation sequencing (NGS), [13] [14] [15] and fluorodeoxyglucose positron-emission tomography/ computed tomography (FDG-PET/CT) 14, 16 ; however, these techniques have not been assessed head to head in a prospective clinical study.
We were motivated to expand our knowledge of effective, nonintensive anti-MM therapy. Specifically, we administered CRd therapy followed by lenalidomide extension (CRd-R) to patients with NDMM and studied MRD in the absence of PN of grade at least 3. Furthermore, the same treatment combination was studied in patients with high-risk SMM, a population in which, if left untreated, median time to symptomatic disease progression is less than 2 years.
Methods
The studies in patients with NDMM (NCT01402284) and SMM (NCT01572480) were approved by the National Cancer Institute Institutional Review Board and complied with the Declaration of Helsinki, the International Conference on Harmonisation, and the Guidelines for Good Clinical Practice. All patients provided written informed consent.
Patients
Patients with NDMM or high-risk SMM were eligible for enrollment (see eMethods in the Supplement). Serial MRD monitoring and FDG-PET/CTs were performed at the following time points: baseline, achievement of a CR and/or at the completion of cycles 8, 20, and 32, and at termination of protocol therapy. For MRD assessment using MFC, a discrete population of at least 20 abnormal plasma cells defined MRD-positive disease status. In MRD samples using the NGS LymphoSIGHT (Sequenta, Inc) platform, immunoglobulin-heavy and κ chain variable, diversity, and joining gene segments from genomic DNA obtained from CD138 + bone marrow cell lysate or cell-free supernatant bone marrow aspirate were amplified using universal primer sets as described elsewhere. 13, 19 An MM clonotype was defined as an immunoglobulin rearrangement identified by NGS at a frequency of at least 5%. Additional MRD methodology, FDG-PET/CT responses (adapted from Zamagni et al criteria 16 ), preplanned
Study Design and Procedures

At a Glance
• We administered carfilzomib with lenalidomide and dexamethasone followed by lenalidomide extension to patients with newly diagnosed or smoldering myeloma and studied minimal residual disease in the absence of neuropathy of grade 3 or greater.
• Among 45 patients with newly diagnosed multiple myeloma, none had neuropathy of grade 3 or greater (primary end point).
• Among patients with newly diagnosed multiple myeloma who achieved a near-complete response or better (n = 28), minimal residual disease negativity was 100% by multiparametric flow cytometry and 67% by next-generation sequencing.
• All 12 patients with high-risk smoldering multiple myeloma achieved a very good partial response or better during the study period (primary end point).
• Carfilzomib-lenalidomide-dexamethasone therapy is tolerable and demonstrates deep responses in patients with newly diagnosed or high-risk smoldering multiple myeloma.
Results
Patients and Treatment
Between July 11, 2011, and October 9, 2013, 45 patients with NDMM were enrolled and treated with the outlined treatment regimen. Given promising early results with patients with NDMM, a pilot study (N = 12) investigating the same treatment regimen in high-risk SMM was conducted between May 29, 2012, and April 16, 2013. For NDMM, data cutoff for the analysis was April 4, 2014. Baseline characteristics are summarized in Table 1 . Twentyseven (60%) of the patients with NDMM were male. Median (range) potential follow-up was 17.3 (5.6-31.6) months with a median (range) of 16 (4-30) cycles delivered. The first 20 patients completed at least 2 cycles of therapy without development of PN of grade at least 3; enrollment continued to the full 45 patients. All 45 patients completed 2 cycles and were considered evaluable for the primary end point. At the analysis date, 38 patients continued to receive study therapy; 7 patients discontinued treatment: 4 due to progressive disease (PD) during lenalidomide extension, 1 due to PD during CRd induction, 1 due to personal reasons (obtained sCR and opted not to proceed to lenalidomide extension), and 1 due to cognitive decline. Forty-two patients completed 8 cycles, and 17 patients completed 20 cycles.
All 12 patients with high-risk SMM were evaluable for safety and efficacy. Baseline characteristics are summarized in Table 1 
Safety and Tolerability
No patients with NDMM experienced grade 3 or 4 PN (primary end point); the incidences of grade 1 and 2 PN were 33% and 9%, respectively. The most common any-grade hematologic and nonhematologic adverse events (AEs) among patients with NDMM were lymphopenia and electrolyte or metabolism abnormalities, respectively ( Table 2) . Two of 6 patients with infections of grade 3 or greater had opportunistic infections (Pneumocystis jiroveci and Cryptococcus neoformans, n = 1 each). The specific grade 3 or 4 cardiac events included CHF (n = 2) and hypertension (n = 3). Two patients had clinical symptoms consistent with CHF and elevated pro-brain natriuretic peptide but no change in ejection fractions. Patients with cardiac events were managed medically with fluid management and antihypertensive therapy, and they continued to receive the study medication. Venous thromboembolism developed in 11 (24%) patients. Three secondary malignant neoplasms occurred during study participation (basal cell [n = 2] and squamous cell carcinoma of the skin [n = 1]). Only 1 patient discontinued study therapy (due to cognitive decline), and 20 (44%) patients required dosing modifications
). There were no grade 5 AEs reported in patients with NDMM. High-risk patients with SMM had similar AEs; the most common of any-grade AEs were lymphopenia (100%) and gastrointestinal disorders (n = 11 [92%]). Second primary malignant neoplasms were reported in 2 patients (17%) with nonmelanoma skin cancers. One patient discontinued treatment after cycle 6 of combination therapy, owing to a serious AE of grade 3 CHF; this was assessed as likely being related to carfilzomib therapy. Based on the protocol, 6 patients required dos- Table 3) . Responses improved as patients received more therapy: the CR or sCR rate increased from 7% after 2 cycles to 43% after 8 cycles. Among the 25 patients with NDMM with a CR or sCR, the median (range) time to CR or sCR was 5 (2-17) cycles; 6 patients reached CR or sCR during the lenalidomide extension phase. The median duration of response was not reached; 84% of patients who achieved at least a PR (n = 37) maintained a PR for at least 24 months and 88% of patients who achieved a CR or sCR (n = 22) maintained a CR for at least 24 months (eFigure 2 in the Supplement). Plasma albumin level, which appears to be related to the rate of plasma breakdown of carfilzomib, was noted to be elevated among 4 of 5 patients with clinically progressing disease (P = .004) (see eResults and eFigure 3 in the Supplement).
Results were similar in patients with high-risk SMM. After 2 cycles, all 12 patients had achieved at least a PR; 6 (50%) achieved at least a VGPR. Eleven patients completed 8 cycles; of those, 11 (100% [95% CI, 72%-100%]) had at least a VGPR, including 6 (55% [95% CI, 23%-83%]) with an sCR, 2 (18% [95% CI, 2%-52%]) with a CR, and 3 (27% [95% CI, 6%-61%]) with an nCR. Over the study period, all patients achieved at least a CR. The median (range) time to CR or sCR was 6 (2-20) cycles.
Among . After repeating the analysis (FDG-PET/CT not positive vs positive response), the association between clinical response and FDG-PET/CT response was stronger (Fisher exact test, P = .045). The FDG-PET/CT and MFC responses were evaluated together after CRd and sequentially after 1 year of lenalidomide therapy (Figure 2) .
Overall, the 12-and 18-month Kaplan-Meier estimates for PFS in NDMM were 95% (95% CI, 84%-99%) and 92% (95% CI, 78%-97%), respectively ( Figure 3A) . Median PFS was not reached. Among the 5 patients with NDMM whose disease progressed, 3 have received second-line treatment with high-dose therapy with stem cell rescue and 2 have continued to receive no therapy with monitoring. All 45 patients remain alive. Progression-free survival probabilities at 12 and 18 months for MRD-negative vs MRD-positive patients by MFC after treatment were 100% vs 79% (95% CI, 47%-94%) and 100% vs 63% (95% CI, 30%-87%), respectively (exact 2-tailed log-rank, P < .001) ( Figure 3B ). Estimated 12-and 18-month PFS for MRD-negative vs MRDpositive patients by NGS was 100% vs 95% (95% CI, 75%-99%) and 100% vs 84% (95% CI, 55%-96%), respectively (exact 2-tailed log-rank, P = .02) ( Figure 3C ). At 12 and 18 months, PFS by FDG-PET/CT response negative/decreased vs positive/partial was 100% vs 89% (95% CI, 68%-97%) and 92% (95% CI, 67%-99%) vs 89% (95% CI, 68%-97%), respectively (exact 2-tailed log-rank, P = .54) ( Figure 3D ). No patients with SMM experienced disease progression while participating in the study; all have maintained their best response at the time of data cutoff. Subset analyses of patients with NDMM, including by age, cytogenetic risk group, and presence of extramedullary disease at baseline, are shown in the eResults in the Supplement.
Discussion
In patients with NDMM and SMM, the CRd-R regimen was well tolerated, without emergence of severe, debilitating PN of grade 3 or greater, possibly leading to high rates of MRD-negative disease. Overall, both NDMM and SMM patients experienced infrequent severe AEs and toxic effects of grade 3 or greater. Despite high rates of grade 3 or 4 lymphopenia, atypical infections were limited. Future work is needed to determine which lymphocyte subsets were affected, which may be important when considering rational combinations incorporating immunomodulatory therapies. One patient with SMM experienced an episode of symptomatic CHF with decreased ejection frac- c Three patients were not evaluable after 8 cycles (2 had not completed 8 cycles, and 1 patient's disease had progressed prior to completion of 8 cycles).
d One patient discontinued study participation before completing 8 cycles.
e Twenty-nine patients were not evaluable after 20 cycles (26 patients had not completed 20 cycles, 1 patient's disease had progressed prior to completion of 20 cycles, 1 patient's disease had progressed just after completion of 20 cycles, and 1 patient had discontinued study participation for personal reasons). f Nine patients were not evaluable after 20 cycles (8 patients had not completed 20 cycles, and 1 patient had discontinued study participation before completing 8 cycles).
tion and discontinued treatment after completing 6 cycles and reaching an sCR. The mechanisms underlying this cardiotoxicity are poorly understood. The patient was prescribed cardiac therapy and symptoms reverted back to baseline without any residual symptoms. The patient was monitored with repeated assessment of the ejection fraction and continues to receive cardiac therapy. In patients with NDMM, best overall response rates of at least VGPR and at least nCR were 89% and 62%, respectively. A potential mechanism for poor responses and PFS may be attributed to metabolism of carfilzomib in the plasma. Further work is needed to validate these findings. Importantly, among patients with NDMM achieving at least nCR, MRD-negative disease status was found to be 100% (MFC) and 67% (NGS). Similar to studies that evaluated MRD status after autologous stem cell transplant, 11,12 MRD negativity was associated with improved PFS. Whereas these trials demonstrated that MRD negativity was also associated with prolonged overall survival and the utility of MRD as a surrogate end point is currently being explored, our trial is limited by shortened follow-up and small numbers. A recent phase 3 study with lenalidomide and dexamethasone demonstrated that the treatment of patients with highrisk SMM, a population in which patients generally do not receive treatment per existing guidelines, translated into survival benefits compared with patients who did not receive this regimen. In these patients, a 14% rate of at least CR was observed after combination therapy. Given the clinical successes of the aforementioned highrisk SMM trial and the preliminary response rates seen in the NDMM lenalidomide and dexamethasone extension trial, we designed a pilot study in patients with high-risk SMM. Deeper responses were observed in patients with high-risk SMM than in patients with NDMM (at least nCR rate of 100% vs 62%, respectively). Longer follow-up and additional studies are needed to determine whether deeper responses in high-risk SMM translate into a clinical benefit beyond waiting to treat after symptom development. Although cross-trial comparisons should be viewed cautiously, we conclude that our observed unprecedented high rates of deep response (CR and MRDnegativity) in patients with NDMM or SMM, with the addition of carfilzomib to a lenalidomide and dexamethasone backbone, confirm and expand on prior CRd results, including those from NDMM 8 and patients with relapsed or refractory disease.
10
Given the high degree of CR rates achievable by 3-drug combination regimens, there is an increased need for clinical trials to detect MRD beyond traditional methods and characterize optimal MRD technique. In the past, we have noted substantial heterogeneity in how MFC is used, which has affected MRD detection rates.
23,24 Our current MFC assay (sensitivity of 1 × 10 −5 ) reports 98% negativity among patients with NDMM or SMM who have achieved at least an nCR. The NGS assay was able to detect 30% additional MRDpositive cases among patients who achieved at least an nCR.
Although this result highlights the intermethodologic differences between both platforms and the potential increased sensitivity with NGS, use of both platforms was feasible. The feasibility of MRD measurement was 98% using MFC; for NGS, 93% of patients were able to have baseline calibration. Thus far in follow-up, additional detection of MRD-positive cases using NGS has not significantly affected PFS or survival outcomes. Interestingly, NGS was able to detect MRD in an sCR patient (NDMM) for whom MFC had failed. This patient's disease clinically progressed after 1 year of MRD-positive detection by NGS. The relationship between PET/CT responses and clinical outcomes is less apparent, with no significant association found between the degree of PET/CT response and clinical response, MRD status, or PFS. Further work is needed to characterize residual FDG-avid areas in the context of tumor biology and long-term outcomes.
Conclusions
The present study confirms and expands our knowledge of effective, nonintensive anti-MM therapy, building on previous studies of CRd in relapsed MM 10 and NDMM. 8 Taken together, our results provide further evidence for the role for proteasome inhibitor-immunomodulatory drug combination therapy in NDMM and demonstrate that MRD evaluation may 
